These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 29191244)

  • 21. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
    Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
    Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
    Shah RR
    Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death.
    Wolbrette DL
    Curr Cardiol Rep; 2004 Sep; 6(5):379-84. PubMed ID: 15306095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced torsades de pointes in patients aged 80 years or more.
    Paran Y; Mashav N; Henis O; Swartzon M; Arbel Y; Justo D
    Anadolu Kardiyol Derg; 2008 Aug; 8(4):260-5. PubMed ID: 18676301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL; Pollard CE; Hammond TG; Valentin JP
    J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Approach to initiating QT-prolonging oncology drugs in the ambulatory setting.
    de Lemos ML; Kung C; Kletas V; Badry N; Kang I
    J Oncol Pharm Pract; 2019 Jan; 25(1):198-204. PubMed ID: 29298624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents.
    Jardin CG; Putney D; Michaud S
    Ann Pharmacother; 2014 Feb; 48(2):196-202. PubMed ID: 24301687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients.
    Schächtele S; Tümena T; Gaßmann KG; Fromm MF; Maas R
    PLoS One; 2016; 11(5):e0155649. PubMed ID: 27192430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prescription and Dispensation of QT-Prolonging Medications in Individuals Receiving Hemodialysis.
    Wang V; Wang CL; Assimon MM; Pun PH; Winkelmayer WC; Flythe JE
    JAMA Netw Open; 2024 Apr; 7(4):e248732. PubMed ID: 38687480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.
    Mok NS; Lo YK; Tsui PT; Lam CW
    J Cardiovasc Electrophysiol; 2005 Dec; 16(12):1375-7. PubMed ID: 16403073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Risk management of QT-prolonging drugs by community pharmacists using a mobile electrocardiograph].
    Shinozaki K
    Yakugaku Zasshi; 2010 Nov; 130(11):1597-601. PubMed ID: 21048421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial agents-associated with QT interval prolongation.
    Bril F; Gonzalez CD; Di Girolamo G
    Curr Drug Saf; 2010 Jan; 5(1):85-92. PubMed ID: 20210724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
    Lin YL; Kung MF
    Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
    Pearson EC; Woosley RL
    Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leading 20 drug-drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients.
    Das B; Ramasubbu SK; Agnihotri A; Kumar B; Rawat VS
    Ther Adv Cardiovasc Dis; 2021; 15():17539447211058892. PubMed ID: 34841978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of Medication Associated with QTc Prolongation Used Among Critically Ill Patients.
    Al-Azayzih A; Al-Qerem W; Al-Azzam S; Muflih S; Al-Husein BA; Kharaba Z; Kanaan RJ; Rahhal D
    Vasc Health Risk Manag; 2024; 20():27-37. PubMed ID: 38318252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.
    Sarganas G; Garbe E; Klimpel A; Hering RC; Bronder E; Haverkamp W
    Europace; 2014 Jan; 16(1):101-8. PubMed ID: 23833046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What clinicians should know about the QT interval.
    Al-Khatib SM; LaPointe NM; Kramer JM; Califf RM
    JAMA; 2003 Apr 23-30; 289(16):2120-7. PubMed ID: 12709470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of torsades de pointes in older patients with drug-associated long QT syndrome: a case-control study.
    Goutelle S; Sidolle E; Ducher M; Caron J; Timour Q; Nony P; Gouraud A
    Drugs Aging; 2014 Aug; 31(8):601-9. PubMed ID: 24923384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.